Shire PLC’s (SHPG) Buy Rating Reaffirmed at Citigroup Inc.
Several other research firms have also recently issued reports on SHPG. Zacks Investment Research upgraded shares of Shire PLC from a sell rating to a hold rating in a research note on Thursday, August 4th. Jefferies Group restated a buy rating and set a $262.00 price objective on shares of Shire PLC in a research report on Wednesday, September 7th. BTIG Research restated a buy rating and set a $230.00 price objective on shares of Shire PLC in a research report on Tuesday, July 12th. Morgan Stanley restated an overweight rating on shares of Shire PLC in a research report on Friday, June 3rd. Finally, JPMorgan Chase & Co. restated an overweight rating on shares of Shire PLC in a research report on Monday, August 1st. Five equities research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $230.67.
Shares of Shire PLC (NASDAQ:SHPG) traded down 0.19% during mid-day trading on Tuesday, hitting $199.83. 119,305 shares of the stock were exchanged. The stock’s 50-day moving average price is $196.32 and its 200-day moving average price is $185.34. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32. The company has a market cap of $59.52 billion, a P/E ratio of 41.53 and a beta of 1.11.
Shire PLC (NASDAQ:SHPG) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.35. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The firm earned $2.43 million during the quarter, compared to analysts’ expectations of $2.28 billion. During the same period in the previous year, the business posted $2.63 EPS. The business’s revenue was up 55.9% compared to the same quarter last year. Equities research analysts anticipate that Shire PLC will post $12.93 earnings per share for the current fiscal year.
The company also recently disclosed a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be given a $0.139 dividend. The ex-dividend date is Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is 15.63%.
A number of institutional investors have recently bought and sold shares of SHPG. Norges Bank acquired a new stake in Shire PLC during the fourth quarter worth approximately $31,671,000. BTC Capital Management Inc. increased its stake in Shire PLC by 12.5% in the first quarter. BTC Capital Management Inc. now owns 1,213 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 135 shares during the period. Exane Asset Management acquired a new stake in Shire PLC during the first quarter worth approximately $12,851,000. Ngam Advisors L.P. increased its stake in Shire PLC by 22.8% in the first quarter. Ngam Advisors L.P. now owns 34,151 shares of the biopharmaceutical company’s stock worth $5,870,000 after buying an additional 6,333 shares during the period. Finally, Connable Office Inc. increased its stake in Shire PLC by 17.5% in the first quarter. Connable Office Inc. now owns 2,205 shares of the biopharmaceutical company’s stock worth $379,000 after buying an additional 328 shares during the period. Hedge funds and other institutional investors own 24.26% of the company’s stock.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.